This document summarizes a study that analyzed cancer treatment guidelines from the National Comprehensive Cancer Network (NCCN) to build two networks: 1) a drug-to-cancer bipartite network showing which drugs are recommended to treat which cancers, and 2) an unipartite drug-to-drug network showing which drugs are commonly used together in treatment regimens. Key findings include that cancers treated with more drugs tended to have higher "despair" indices, and that cytotoxic drugs and the drug rituximab had high betweenness centrality in the drug network, indicating their importance in treatment regimens. Limitations included the small number of cancers and drugs studied due to data availability.